Catalysts · VNDA · CIK 1347178 · page 2 of 2

VNDA catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on VNDA PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
Dec 2024Month disclosedHETLIOZ® (tasimelteon)VNDAFDA approval—ApprovedSEC Form 10-Q
Dec 2024Month disclosedgenericVNDAFDA approval—ApprovedSEC Form 10-K
September 18, 2024NEREUSTM (tradipitant)VNDAPDUFA datesymptoms of gastroparesis to a final decision priorCRL issuedSEC Form 10-Q
September 18, 2024NEREUSTM (tradipitant)VNDAComplete Response Letter—CRL issuedSEC Form 10-K
March 4, 2024—VNDAComplete Response Letter—CRL issuedSEC Form 10-K
March 4, 2024HETLIOZ® (tasimelteon)VNDAPDUFA date—ScheduledSEC Form 10-K
Jan 2024Month disclosedVTR-297VNDAFDA approvalonychomycosis, a fungal infection of the nailApprovedSEC Form 10-K
Jan 2024Month disclosedVCA-894AVNDAFDA approvalpatient with CMT2SApprovedSEC Form 10-K
Dec 2023Month disclosedNEREUSTM (tradipitant)VNDANDA/BLA accepted—CompletedSEC Form 10-K
Dec 2023Month disclosedNEREUSTM (tradipitant)VNDAFDA approvalvomiting inducedApprovedSEC Form 10-K
Jul 2023Month disclosedHETLIOZ® (tasimelteon)VNDANDA/BLA accepted—CompletedSEC Form 10-K
Dec 2022Month disclosedHETLIOZ® (tasimelteon)VNDAFDA approval—ApprovedSEC Form 10-Q
Dec 2022Month disclosedgenericVNDAFDA approval—ApprovedSEC Form 10-K
Sep 2022Month disclosedHETLIOZ® (tasimelteon)VNDANDA/BLA submissionjet lag disorderCompletedSEC Form 10-Q
Every catalyst is quoted from VNDA’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.